# SAB Biotherapeutics (SABS) — Analyst Forecast

SABS · NASDAQ · Stock

Canonical page: https://www.lighthorse.io/tickers/sabs/forecast

## Analyst consensus

| Consensus | Buy | Hold | Sell | Analysts |
| --- | --- | --- | --- | --- |
| Buy | 12 | 0 | 0 | 12 |

## Recent analyst ratings

| Date | Firm | Action | Rating | Price target |
| --- | --- | --- | --- | --- |
| Jun 24, 2026 | Barclays | Initiated Coverage | Overweight | $13.00 |
| Jun 17, 2026 | Chardan Capital | Maintained | Buy | $16.00 |
| Jun 15, 2026 | HC Wainwright & Co. | Maintained | Buy | $10.00 |
| Jun 15, 2026 | Leerink Partners | Maintained | Outperform | $12.00 |
| May 22, 2026 | Citigroup | Initiated Coverage | Buy | $11.00 |
| May 20, 2026 | Jefferies | Initiated Coverage | Buy | $11.00 |
| May 12, 2026 | HC Wainwright & Co. | Maintained | Buy | $10.00 |
| May 11, 2026 | Rodman & Renshaw | Maintained | Buy | $13.00 |
| Mar 11, 2026 | Chardan Capital | Maintained | Buy | $14.00 |
| Mar 10, 2026 | HC Wainwright & Co. | Maintained | Buy | $7.00 |
| Jan 7, 2026 | UBS | Initiated Coverage | Buy | $7.00 |
| Dec 19, 2025 | Guggenheim | Initiated Coverage | Buy | $15.00 |
| Dec 18, 2025 | Chardan Capital | Maintained | Buy | $12.00 |
| Nov 17, 2025 | Chardan Capital | Maintained | Buy | $12.00 |
| Sep 19, 2025 | Chardan Capital | Maintained | Buy | $12.00 |
| Sep 17, 2025 | Leerink Partners | Initiated Coverage | Outperform | $7.00 |
| Aug 8, 2025 | Chardan Capital | Maintained | Buy | $12.00 |
| Jul 22, 2025 | HC Wainwright & Co. | Maintained | Buy | $9.00 |
| May 15, 2025 | Chardan Capital | Maintained | Buy | $20.00 |
| May 14, 2025 | HC Wainwright & Co. | Initiated Coverage | Buy | $10.00 |

## Frequently Asked Questions

### Is SABS a buy, sell, or hold?

Analysts covering SAB Biotherapeutics currently average a Buy rating: 12 buy, 0 hold and 0 sell, from 12 analysts. Ratings reflect analyst opinion, not investment advice.

### What is the latest analyst rating on SABS?

On Jun 24, 2026, Barclays initiated coverage of SAB Biotherapeutics at Overweight with a price target of $13.00.

---

Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).